Literature DB >> 15502410

Delayed HIV-1 infection of CD4+ T lymphocytes from therapy-naïve patients demonstrated by quantification of HIV-1 DNA copy numbers.

Kaoru Wada1, Hiromi Nagai, Tomoko Hagiwara, Shiro Ibe, Makoto Utsumi, Tsuguhiro Kaneda.   

Abstract

Measuring the amount of HIV-1 DNA in infected cells is important to estimate the size of the viral reservoir in patients. However, the clinical impact of the intracellular viral DNA level remains unclear. The present study examines the clinical significance of the HIV-1 DNA level in peripheral CD4+ T lymphocytes from 21 therapy-naïve patients. HIV-1 DNA levels in purified peripheral CD4+ T lymphocytes were measured by the real-time PCR method using the Roche LightCycler system that can detect 200 copies/10(6) cells. We detected intracellular HIV-1 DNA in 15 (71.4%) of 21 patients at levels ranging from 270 to 98,120 copies/10(6) CD4+ cells, with a median of 2,220 copies/10(6) cells. We also found HIV-1 DNA that was below the detection limit in the remaining 6 patients, although 8,800-150,000 copies/ml of HIV-1 RNA were detected in plasma. Circular HIV-1 DNA was not detected in 5 of 6 cases, suggesting that reverse transcription in CD4+ T lymphocytes of these cases was not active. Thus, delayed HIV-1 infection of CD4+ T lymphocytes was demonstrated in these patients. The level of HIV-1 DNA in peripheral CD4+ T lymphocytes indicates the clinical status of therapy-naïve patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15502410     DOI: 10.1111/j.1348-0421.2004.tb03603.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  1 in total

1.  Cellular HIV-1 DNA levels in patients receiving antiretroviral therapy strongly correlate with therapy initiation timing but not with therapy duration.

Authors:  Dai Watanabe; Shiro Ibe; Tomoko Uehira; Rumi Minami; Atsushi Sasakawa; Keishiro Yajima; Hitoshi Yonemoto; Hiroki Bando; Yoshihiko Ogawa; Tomohiro Taniguchi; Daisuke Kasai; Yasuharu Nishida; Masahiro Yamamoto; Tsuguhiro Kaneda; Takuma Shirasaka
Journal:  BMC Infect Dis       Date:  2011-05-24       Impact factor: 3.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.